title: Third annual forum on T-cell lymphoma.
abstract: The Third Annual T-cell Lymphoma Forum, held on 27-29 January 2011 in San Francisco (CA, USA), continued in the spirit of the two earlier conferences and provided a collegial venue for clinicians and scientists to discuss advances in the science and treatment of T-cell lymphomas. More than 40 experts from around the world presented updates on classification, epidemiology and prognosis; rare and T-cell lymphomas of unspecified origin, CD30(+) T-cell lymphomas; new treatment strategies; new agents and rational combinations; and transplantation. Of particular interest this year was a discussion on the link between breast implants and anaplastic large-cell lymphoma, which coincided with the US FDA announcement of this rare but noteworthy relationship. Submitted abstracts and poster presentations rounded off each of the sessions.
authors.affiliation: Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. ktobinai@ncc.go.jp
authors.forename: Kensei
authors.initials: K
authors.lastname: Tobinai
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018427:Breast Implants / Q000009:adverse effects; D003131:Combined Modality Therapy; D006801:Humans; D017730:Ki-1 Antigen / Q000378:metabolism; D017728:Lymphoma, Large-Cell, Anaplastic / Q000209:etiology; D016399:Lymphoma, T-Cell / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D017730:Ki-1 Antigen